NCT03562130View on ClinicalTrials.gov

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

July 13, 2020

Conditions

Short Bowel Syndrome

Interventions

DRUG

Teduglutide

Daily sub cutaneous injection 0,05 mg/kg/day

Trial Locations (1)

75015

Hôpital Necker - Enfants malades, Paris

Sponsors

Collaborators (1)

Imagine Institute

All Listed Sponsors

collaborator

Imagine Institute

OTHER

collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER